Platelet-Activating Factor Production From In Vitro and In Vivo Fertilized Murine Embryos Is Similar
Article first published online: 9 MAY 2013
American Journal of Reproductive Immunology
Volume 30, Issue 2-3, pages 101–104, September-October 1993
How to Cite
RIPPS, B.A., ZHU, Y.P., BURWINKEL, T.H., KIM, H.N., BUSTER, J.E. and MINHAS, B.S. (1993), Platelet-Activating Factor Production From In Vitro and In Vivo Fertilized Murine Embryos Is Similar. American Journal of Reproductive Immunology, 30: 101–104. doi: 10.1111/j.1600-0897.1993.tb00609.x
- Issue published online: 9 MAY 2013
- Article first published online: 9 MAY 2013
- Accepted June 28, 1993
- Embryo-derived PAF;
PROBLEM: This study measured platelet-activating factor (PAF) production of in vitro and in vivo fertilized murine embryos to ascertain whether site of fertilization impacted subsequent embryonic PAF production.
METHOD: Ooocytes and embryo were collected from stimulated B6D2F1 mice. PAF production throughout the preimplantation phase from the two-celled stage through expanded blastocysts was measured and compared among normally developing embryos with the only difference being site of fertilization.
RESULTS: A striking increase in PAF production was noted for both in vivo and in vitro fertilized embryos over the four days of culture. Significantly higher (P<.001) levels of PAF production were noted with development from the two-celled stage (47.22 ± 4.13; 44.30 ± 2.43) to expanded blastocysts (254.31 ± 24.01;255.11 ± 5.35 ng/embryo/24h)forbothin vitro and in vivo fertilized embryos, respectively. There was no significant difference (P>.05) in PAF production between the two groups of embryos.
CONCLUSIONS: Embryonic PAF production in the mouse increases in a stage-specific manner, and specifically the site of fertilization in vitro versus in vivo does not affect PAF production in normally developing embryos.